Efficacy of Botulinum Toxin Type-A I in the Improvement of Mandibular Motion and Muscle Sensibility in Myofascial Pain TMD Subjects: A Randomized Controlled Trial
Giancarlo De la Torre Canales,
Rodrigo Lorenzi Poluha,
Natalia Alvarez Pinzón,
Bruno Rodrigues Da Silva,
Andre Mariz Almeida,
Malin Ernberg,
Ana Cristina Manso,
Leonardo Rigoldi Bonjardim,
Célia Marisa Rizzatti-Barbosa
Affiliations
Giancarlo De la Torre Canales
Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Egas Moniz—Cooperativa de Ensino Superior, CRL, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal
Rodrigo Lorenzi Poluha
Department of Dentistry, State University of Maringa, Maringa 87020-900, Brazil
Natalia Alvarez Pinzón
Institución Universitaria Colegios de Colombia-Centro de Investigación del Colegio Odontológico (CICO) 20, Bogotá 111611, Colombia
Bruno Rodrigues Da Silva
Private Practice—Boavista Avenue, 4100-139 Porto, Portugal
Andre Mariz Almeida
Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Egas Moniz—Cooperativa de Ensino Superior, CRL, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal
Malin Ernberg
Department of Dental Medicine, Karolinska Institutet, and the Scandinavian Center for Orofacial Neurosciences (SCON), 141 52 Huddinge, Sweden
Ana Cristina Manso
Clinical Research Unit (CRU), Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Egas Moniz—Cooperativa de Ensino Superior, CRL, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal
Leonardo Rigoldi Bonjardim
Bauru Orofacial Pain Group, Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Sao Paulo 17012-900, Brazil
Célia Marisa Rizzatti-Barbosa
Ingá University Center, Uningá, Maringa 87020-900, Brazil
This study assessed the effects of botulinum toxin type A (BoNT-A) in mandibular range of motion and muscle tenderness to palpation in persistent myofascial pain (MFP) patients (ReBEC RBR-2d4vvv). Eighty consecutive female subjects with persistent MFP, were randomly divided into four groups (n = 20): three BoNT-A groups with different doses and a saline solution group (placebo control group). Treatments were injected bilaterally in the masseter and anterior temporalis muscle in a single session. Clinical measurements of mandibular movements included: pain-free opening, maximum unassisted and assisted opening, and right and left lateral excursions. Palpation tests were performed bilaterally in the masseter and temporalis muscle. Follow-up occurred 28 and 180 days after treatment. For the statistical analysis the Mann–Whitney U-test with Bonferroni correction was used for groups comparisons. Regardless of dose, all parameters of mandibular range of motion significantly improved after 180 days in all BoNT-A groups, compared with the control group. Palpation pain over the masseter and temporalis muscles were significantly reduced in all BoNT-A groups regardless of dose, compared with the control group, after 28 and 180 days of treatment. Independent of doses, BoNT-A improved mandibular range of motion and muscle tenderness to palpation in persistent MFP patients.
